<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Amlodipine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Amlodipine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Amlodipine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8627" href="/d/html/8627.html" rel="external">see "Amlodipine: Drug information"</a> and <a class="drug drug_patient" data-topicid="10852" href="/d/html/10852.html" rel="external">see "Amlodipine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F133997"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Katerzia;</li>
<li>Norliqva;</li>
<li>Norvasc</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865898"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Amlodipine;</li>
<li>ACT AmLODIPine;</li>
<li>AG-AmLODIPine;</li>
<li>APO-AmLODIPine;</li>
<li>Auro-AmLODIPine;</li>
<li>BIO-AmLODIPine;</li>
<li>DOM-AmLODIPine;</li>
<li>JAMP-AmLODIPine;</li>
<li>M-Amlodipine;</li>
<li>Mar-AmLODIPine;</li>
<li>MINT-AmLODIPine;</li>
<li>MYLAN-AmLODIPine;</li>
<li>Norvasc;</li>
<li>NRA-Amlodipine;</li>
<li>PDP-Amlodipine;</li>
<li>PHARMA-AmLODIPine;</li>
<li>PMS-AmLODIPine;</li>
<li>PRZ-Amlodipine;</li>
<li>RIVA-AmLODIPine;</li>
<li>SANDOZ AmLODIPine;</li>
<li>SANDOZ-AmLODIPine;</li>
<li>Septa-AmLODIPine;</li>
<li>TARO-Amlodipine;</li>
<li>TEVA-AmLODIPine [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1051019"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antianginal Agent</span>;</li>
<li>
<span class="list-set-name">Antihypertensive Agent</span>;</li>
<li>
<span class="list-set-name">Calcium Channel Blocker</span>;</li>
<li>
<span class="list-set-name">Calcium Channel Blocker, Dihydropyridine</span></li></ul></div>
<div class="block dop drugH1Div" id="F134022"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;6 years: Limited data available: Oral: Initial: 0.1 mg/kg/dose once daily; titrate based on clinical response; maximum daily dose: 0.6 mg/kg/<b>day </b>or 5 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: Oral: Initial: 2.5 mg once daily; titrate based on clinical response; maximum daily dose: 10 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ceda7e14-ab73-44c4-8ea0-8b7d533fa82c">Raynaud phenomenon, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Raynaud phenomenon, treatment: </b>Very limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: Oral: Usual dosage range: 2.5 to 10 mg once daily; start dose low and increase as tolerated and based on symptom response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19797310','lexi-content-ref-Kliegman.1','lexi-content-ref-Wigley.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19797310','lexi-content-ref-Kliegman.1','lexi-content-ref-Wigley.2'])">Ref</a></span>).<b> Note:</b> In addition to nonpharmacologic interventions (eg, cold avoidance), dihydropyridine calcium channel blockers are recommended for management; although nifedipine has the most data and is generally used first-line, amlodipine is an acceptable alternative (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27941129','lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27941129','lexi-content-ref-Kliegman.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51064785"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥6 years and Adolescents: No dosage adjustment necessary.</p></div>
<div class="block dohp drugH1Div" id="F51257788"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; based on prolonged half-life in severe hepatic impairment and experience in adult patients, dosing adjustment and slow titration suggested.</p></div>
<div class="block doa drugH1Div" id="F134002"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8627" href="/d/html/8627.html" rel="external">see "Amlodipine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c263a8d4-f2ef-49a8-a963-6b87a475dbec">Angina</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angina:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Chronic stable angina (alternative agent):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> A beta-blocker is the preferred initial therapy; if there are ongoing symptoms on beta-blocker therapy, a long acting dihydropyridine calcium channel blocker (eg, amlodipine) may be added; amlodipine may also be used as an alternative therapy if there are contraindications or unacceptable adverse effects with beta-blockade (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23166211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23166211'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 5 to 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Vasospastic angina:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> May use alone or in combination with nitrates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23166211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23166211'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 5 to 10 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: For patients who warrant combination therapy (BP &gt;20/10 mm Hg above goal or suboptimal response to monotherapy), may use with another appropriate agent (eg, angiotensin-converting enzyme [ACE] inhibitor, angiotensin II receptor blocker [ARB], or thiazide diuretic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2.5 to 5 mg once daily; evaluate response after ~2 to 4 weeks and titrate dose, as needed, up to a maximum of 10 mg once daily; if additional blood pressure control is needed, consider combination therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-19052124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-19052124'])">Ref</a></span>); antihypertensive effect attenuates with higher doses and adverse effects may become more prominent. Patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication titration within 1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mann.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mann.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fed0e48d-298d-453f-bda8-97189c608a2d">Raynaud phenomenon</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Raynaud phenomenon (off-label use):</b>
<b>Oral:</b> 5 mg once daily; if needed, increase dose gradually based on patient response and tolerability, usually once every 4 weeks, but not more frequently than once every 7 to 10 days; monitor blood pressure closely with each dose increase; maximum dose: 20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28895508','lexi-content-ref-Wigley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28895508','lexi-content-ref-Wigley.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990964"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS<b>.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b>Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2524389','lexi-content-ref-12845505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2524389','lexi-content-ref-12845505'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): </b>Poorly dialyzed: No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12845505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12845505'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988329"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic stable angina (alternative agent); vasospastic angina:</b>
<b>Oral:</b> Initial: 5 mg once daily; titrate slowly in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic:</b>
<b>Oral:</b> Initial: 2.5 mg once daily; titrate slowly in patients with severe hepatic impairment.</p></div>
<div class="block arsc drugH1Div" id="F54357125"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Peripheral edema</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral edema</b> is the most common adverse reaction with amlodipine, characterized by ankle and leg swelling independent of fluid retention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10679507','lexi-content-ref-11464254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10679507','lexi-content-ref-11464254'])">Ref</a></span>). It is a bothersome adverse reaction for patients and may lead to discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21558959','lexi-content-ref-10679507','lexi-content-ref-11464254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21558959','lexi-content-ref-10679507','lexi-content-ref-11464254'])">Ref</a></span>). Peripheral edema can be expected to subside within several days following intervention.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-and time-related; related to the pharmacologic action. Calcium channel blocker-mediated <b>peripheral edema</b> is caused by arteriolar vasodilation that subsequently leads to increased hydrostatic pressure in the precapillary circulation and fluid movement from the capillary vasculature to the interstitial space (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21558959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21558959'])">Ref</a></span>). In addition, impaired postural vasoconstriction may contribute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11464254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11464254'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; has been reported between 4 weeks to &gt;6 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21558959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21558959'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose-related; doses of 2.5 to 5 mg resulted in lower rates of edema versus 10 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21558959','lexi-content-ref-31107359']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21558959','lexi-content-ref-31107359'])">Ref</a></span>); however, may develop more frequently and at lower doses in patients with impaired postural autoregulation (eg, diabetes, arterial disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11464254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11464254'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration-related (&gt;6 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21558959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21558959'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females</p>
<p style="text-indent:-2em;margin-left:6em;">• Dihydropyridine calcium channel blockers (DHPs) versus non-DHPs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21558959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21558959'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Lipophilic DHPs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21558959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21558959'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F133964"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Cardiovascular: Peripheral edema (2% to 11%, dose related; females: 15%; males: 6%)<span class="lexi-table-link-container"> (<a aria-label="Amlodipine: Adverse Reaction: Peripheral Edema table link" class="lexi-table-link" data-table-id="lexi-content-amlodipine-adverse-reaction-peripheral-edema" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-amlodipine-adverse-reaction-peripheral-edema')">table 1</a>)</span><span class="table-link" style="display:none;">Amlodipine: Adverse Reaction: Peripheral Edema</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Amlodipine: Adverse Reaction: Peripheral Edema" frame="border" id="lexi-content-amlodipine-adverse-reaction-peripheral-edema" rules="all">
<caption style="text-align:center;">
<b>Amlodipine: Adverse Reaction: Peripheral Edema</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Amlodipine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Amlodipine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">512</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">336</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,218</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">914</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">268</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">520</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">296</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">520</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">275</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">520</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (≤3%, dose related, more frequent in females), palpitations (≤5%, dose related, more frequent in females)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (≤2%), skin rash (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2%), nausea (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Male sexual disorder (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (≤2%), dizziness (doses ≥5 mg/day: 3%), drowsiness (1% to 2%), fatigue (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (≤2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral ischemia, sinus tachycardia, syncope, vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, erythema multiforme</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash, hyperglycemia, weight gain, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, constipation, dysphagia, flatulence, gingival hyperplasia, pancreatitis, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Difficulty in micturition, female sexual disorder, nocturia, urinary frequency</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia, purpuric disease, thrombocytopenia (Cvetković 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams, anxiety, depersonalization, depression, hypoesthesia, insomnia, malaise, pain, paresthesia, peripheral neuropathy, rigors, tremor, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, osteoarthritis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, diplopia, eye pain</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrioventricular node dysfunction (BRASH syndrome: Bradycardia, renal failure syndrome, atrioventricular block, shock, hyperkalemia) (Gouveia 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatologic disorder (Schamberg's disease) (Schetz 2015), psoriasis (Song 2021), toxic epidermal necrolysis (Baetz 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gynecomastia (Cornes 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gingival hyperplasia (John 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Ascites (Arasan 2020), cholestatic hepatitis (Egbuonu 2019; Zinsser 2004), hepatotoxicity (Demirci 2013; Hammerstrom 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Akathisia (Dressler 2014), parkinsonism (Teive 2002), tardive dystonia (Dressler 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Subacute cutaneous lupus erythematosus (Mizuta 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute interstitial nephritis (Ejaz 2000)</p></div>
<div class="block coi drugH1Div" id="F133979"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to amlodipine or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Hypersensitivity to other dihydropyridines; severe hypotension (systolic BP &lt;90 mm Hg); breastfeeding; shock (including cardiogenic shock); obstruction of the outflow tract of the left ventricle (eg, high-grade aortic stenosis); hemodynamically unstable heart failure after acute myocardial infarction; hereditary fructose intolerance (oral solution); hyperglycerolemia or glycerol kinase deficiency (oral solution).</p></div>
<div class="block war drugH1Div" id="F133961"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: Symptomatic hypotension can occur; acute hypotension upon initiation is unlikely due to the gradual onset of action. Blood pressure must be lowered at a rate appropriate for the patient's clinical condition.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aortic stenosis: Use amlodipine with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: With the exception of amlodipine, calcium channel blockers should be avoided whenever possible in patients with heart failure with reduced ejection fraction (HFrEF). Amlodipine may be used for the treatment of hypertension or ischemic heart disease in patients with HFrEF, but has no effect on functional status or mortality (AHA/ACC/HFSA [Heidenreich 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; may require lower starting dose; titrate slowly in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertrophic cardiomyopathy with left ventricular outflow tract obstruction: Use amlodipine with caution in patients with hypertrophic cardiomyopathy and left ventricular outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition (AHA/ACC [Ommen 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP 1997; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ethanol: Oral solution contains 4% v/v ethyl alcohol.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Initiate at a lower dose in the elderly.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Titration: Peak antihypertensive effect is delayed; dosage titration should occur after 7 to 14 days on a given dose.</p></div>
<div class="block foc drugH1Div" id="F133971"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as besylate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Norliqva: 1 mg/mL (150 mL) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral, as benzoate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Katerzia: 1 mg/mL (150 mL) [contains polysorbate 80, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as besylate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Norvasc: 2.5 mg, 5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg, 10 mg</p></div>
<div class="block geq drugH1Div" id="F133957"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F133981"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Norliqva Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $4.12</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Katerzia Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $4.70</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (amLODIPine Besylate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $0.06 - $1.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.06 - $1.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.07 - $2.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Norvasc Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $9.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $9.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $13.27</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865899"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as besylate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (150 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as besylate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Norvasc: 5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg, 10 mg</p></div>
<div class="block exp drugH1Div" id="F133977"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Commercial oral liquid preparations are available (1 mg/mL).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>1 mg/mL Oral Suspension</b></p>
<p style="text-indent:-2em;margin-left:4em;">A 1 mg/mL oral suspension may be made with tablets and either a 1:1 mixture of simple syrup and 1% methylcellulose or a 1:1 mixture of Ora-Plus and Ora-Sweet. Crush fifty 5 mg tablets in a mortar and reduce to a fine powder. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 250 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 250 mL. Label "shake well" and "refrigerate". Stable for 56 days at room temperature or 91 days refrigerated.</p>
<div class="reference">Nahata MC, Morosco RS, and Hipple TF. Stability of Amlodipine Besylate in Two Liquid Dosage Forms. <i>J Am Pharm Assoc (Wash).</i> 1999;39(3):375-377.<span class="pubmed-id">10363465</span></div>
</div>
<div class="block admp drugH1Div" id="F52612224"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to food.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: Shake well before using.</p></div>
<div class="block adm drugH1Div" id="F133975"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer without regard to meals. Shake suspension well before using. Administer with an accurate measuring device (calibrated oral syringe or measuring cup); do not use a household teaspoon to measure dose.</p></div>
<div class="block sts drugH1Div" id="F133993"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Solution: Store at 20°C to 25°C (68°F to 77°F); excursion permitted to 15°C to 30°C (59°F to 86°F). Store and dispense in original container.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: Store at 2°C to 8°C (36°F to 46°F); avoid freezing and excessive heat. Protect from light.</p>
<p style="text-indent:0em;">Tablets: Store at 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F53565366"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of hypertension (FDA approved in ages ≥6 years and adults); chronic stable angina (FDA approved in adults); vasospastic (Prinzmetal) angina (FDA approved in adults); angiographically documented coronary artery disease (to decrease risk of hospitalization [due to angina] and coronary revascularization procedure) (FDA approved in adults); has also been used in the treatment of Raynaud phenomenon.</p></div>
<div class="block mst drugH1Div" id="F134051"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">AmLODIPine may be confused with aMILoride</p>
<p style="text-indent:-2em;margin-left:4em;">Norvasc may be confused with Navane, Norvir, Vascor</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Norvasc [US, Canada, and multiple international markets] may be confused with Vascor brand name for imidapril [Philippines] and simvastatin [Malaysia, Singapore, and Thailand]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F134037"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F133966"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Charcoal, Activated: May decrease the serum concentration of AmLODIPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of AmLODIPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of AmLODIPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of AmLODIPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of AmLODIPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: AmLODIPine may diminish the therapeutic effect of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dantrolene: May enhance the hyperkalemic effect of Calcium Channel Blockers. Dantrolene may enhance the negative inotropic effect of Calcium Channel Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhalational Anesthetics: May enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant.  Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lonafarnib.  Management: Avoid concurrent use of lonafarnib with weak CYP3A4 inhibitors. If concurrent use is unavoidable, reduce the lonafarnib dose to or continue at a dose of 115 mg/square meter. Monitor for evidence of arrhythmia, syncope, palpitations, or similar effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: AmLODIPine may increase the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the adverse/toxic effect of Calcium Channel Blockers (Dihydropyridine). Specifically, the risk of hypotension or muscle weakness may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: AmLODIPine may increase the serum concentration of Red Yeast Rice. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: AmLODIPine may increase the serum concentration of Simvastatin.  Management: Dose of simvastatin should not exceed 20 mg daily if coadministering with amlodipine. If coadministering with simvastatin and amlodipine, close laboratory and clinical monitoring for signs and symptoms of rhabdomyolysis is warranted.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a weak CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant.  Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F58530364"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be used in patients trying to conceive. Amlodipine is not considered a preferred agent for use in pregnant patients; consider transitioning to a preferred agent in patients planning to become pregnant (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).</p></div>
<div class="block pri drugH1Div" id="F133982"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Amlodipine crosses the placenta. Cord blood concentrations were ~40% of maternal serum at delivery, and concentrations in the newborn were below the limit of quantification (&lt;0.1 ng/mL) when measured in eight infants within 48 hours of delivery (Morgan 2017; Morgan 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced pharmacologic changes, amlodipine pharmacokinetics may be altered immediately postpartum (Morgan 2018; Naito 2015b; Taguchi 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of hypertension is initiated during pregnancy, agents other than amlodipine may be preferred (ACOG 2019; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]).</p></div>
<div class="block mopp drugH1Div" id="F53565365"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure, heart rate, liver enzymes.</p></div>
<div class="block pha drugH1Div" id="F133960"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits calcium ion from entering the “slow channels” or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina. Amlodipine directly acts on vascular smooth muscle to produce peripheral arterial vasodilation reducing peripheral vascular resistance and blood pressure.</p></div>
<div class="block phk drugH1Div" id="F133978"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Antihypertensive effect: Significant reductions in blood pressure at 24 to 48 hours after first dose; slight increase in heart rate within 10 hours of administration may reflect some vasodilating activity (Donnelly 1993).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Antihypertensive effect: At least 24 hours (Donnelly 1993); has been shown to extend to at least 72 hours when discontinued after 6 to 7 weeks of therapy (Biston 1999).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed (Meredith 1992).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Mean V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;6 years: Similar to adults on a mg per kg basis; <b>Note: </b>Weight-adjusted V<sub>d</sub> in younger children (&lt;6 years of age) may be greater than in older children (Flynn 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 21 L/kg (Scholz 1997).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~93%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (~90%) to inactive metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 64% to 90%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal (biphasic): 30 to 52 hours; increased with hepatic dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 6 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (10% of total dose as unchanged drug, 60% of total dose as metabolites).</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance: May be decreased in patients with hepatic insufficiency or moderate to severe heart failure; weight-adjusted clearance in children &gt;6 years of age is similar to adults; <b>Note:</b> Weight-adjusted clearance in younger children (&lt;6 years of age) may be greater than in older children (Flynn 2006).</p></div>
<div class="block phksp drugH1Div" id="F51220433"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC may increase ~40% to 60%.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: AUC may increase ~40% to 60%.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe heart failure: AUC may increase ~40% to 60%.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F133984"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Amlo | Amlocard | Amlopress | Amlosafe | Amlosin | Amneo | Istin | Lofral | Maldocardin | Norvasc | Stamlo | Vascodipine</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Amloc | Amlodicord | Amlodine | Amlodipina | Amlodipina Denver farma | Amlodipina ilab | Amlodipina richet | Amlodipina tauro | Amlodipina vannier | Amlodisane | Amlopaw | Amlosidane | Amze | Anexa | Angiofilina | Angipec | Arteriosan | Brancilina | Calpres | Cardivas | Cordiax | Coroval | Dronalden | Hipertensal | Ilduc | Indalten | Mitokor | Nexotensil | Nikor | Oteramina | Pelmec | Terloc | Tervalon | Verodipin | Zundic</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Amlodibene | Amlodilan | Amlodinova | Amlodipin 1a pharma gmbh | Amlodipin accord | Amlodipin actavis | Amlodipin arcana | Amlodipin Arcana | Amlodipin besilat stada | Amlodipin bluefish | Amlodipin G.L. | Amlodipin genericon pharma | Amlodipin hexal pharma | Amlodipin interpharm | Amlodipin mylan | Amlodipin Ratiopharm | Amlodipin sandoz | Amlodipin stada arzneimittel gmbh | Amlodipin Teva | Amlopin s | Amlotyrol | Coradipin | Norvasc</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Amlodipine | Amlodipine an | Amlodipine apotex | Amlodipine Drla | Amlodipine Generic Health | Amlodipine sandoz | Auro Amlodipine | Nordip | Norvapine | Norvasc | Noumed amlodipine | Ozlodip | Perivasc</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Alopin | Amdin | Amdocal | Amdopin | Amlo | Amlocard | Amlodin | Amlopin | Amlopress | Amlosun | Amlovas | Amocal | Ampil | Ampre | Amtinol | Cab | Calchek | Calock | Calpin | Calpress | Calvasc | Camlodin | Cardifort | Cardipin | Cardolab | Cardosia | Ccb | Cordil | Cvnor | Dilopin | Dipicard | Dopin | Emlon | Hipre | Imped | Ipin | Locard | Lodipin | Lopin | Lovapres | Nelod | Nopidin | Olipin | Pristin | Sb amlod | Sidopin | Vasopin | Vesocal | Xelcard</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Amlodipin ab | Amlodipine arrow | Amlodipine Besilaat Sandoz | Amlodipine Besilaate Sandoz | Amlodipine besilate Docpharma | Amlodipine Besilate EG | Amlodipine Besilate Ratiopharm | Amlodipine bexal | Amlodipine Ivowen | Amlodipine krka | Amlodipine merck-generics | Amlodipine ratiopharm | Amlodipine sandoz | Docamlodipine | Provasc</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Amapine | Amep | Amlibon | Amlo denk | Amlo h | Amloclass | Amlong | Amlonorm | Amlopres | Amlor | Amlostar | Amlowin | Calcheck | Circagard | Fairdipin | Lofral | Lopin</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Accel | Agen | Amlocor | Amlodicon | Amlodigamma | Amlodipin | Amlodipine biopharm | Amlodipine ecopharm | Amlodipine Medica | Amlopin | Amloteron | Amlovask | Neodipin Bes T | Normodipin | Norvasc | Tenox</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alivpress | Amelovas | Amilopil | Amlocor | Amlodil | Amloprax | Amlovasc | Anlo | Anlodibal | Anlodil | Anlusbed | Besilapin | Besilato de anlodipino | Cordarex | Cordipina | Lodipen | Lodipil | Nemodine | Nicord | Norvasc | Pressat | Roxflan | Tenlopin | Tensaliv | Tensidipin | Tensodin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Amlo | Amlo eco | Amlodipin Actavis | Amlodipin Axapharm | Amlodipin besilat 1 a pharma | Amlodipin Besilat Teva | Amlodipin Cimex | Amlodipin HelvePharm | Amlodipin Orion | Amlodipin Pfizer | Amlodipin sandoz eco | Amlodipin Spirig | Amlodipin spirig hc | Amlodipin Zentiva | Amlodipin-Mepha | Norvasc</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Amaday | Amapine | Amcard | Amep | Amilo | Amlibon | Amlo h | Amlocor | Amlodipine | Amlodis | Amlong | Amlopres | Amlor | Amlostar | Amlotensine | Amlowel | Amlowin | Amoclass | Anglor | Asomex | Calcinib | Creadipine | Gardilong | Lopine | Pimlo | Ronamlo | Varinil | Zocard</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Amdipin | Amloc | Amlodipino | Ampino | Avirin | Lomakare | Molsicor | Norvasc | Presilam | Presovasc | Terloc</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Amlodipine | Amlodipine besylate | An nei zhen | Ao wan lu | Aspartic acid amlodipine | Bi luo ping | Jiu bao shu | Ke ping | Lan di | Li si de | Luo he xi | Mai li ping | Ming yi | Ning li ping | Norvasc | Nuo er ma | Pu luo xin xi | Sa bo ni | Sai li de | Shen yi kang lin | Shu le kang | Tian wu | Xi luo ning | XinLuoPing | Ya bang bei di | Ya shi da | Ya si ke ping | Yi lu jing</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Abalpin | Alidona | Amcardia | Amdipin | Amigard | Amlodip | Amlodipino | Amlodipino MK | Amlosyn | Amlovas | Cardinor | Eucoran | Micior | Norvas | Rivam | Samlopharis | Vasten</span>;</li>
<li>
<span class="countryCode">(CR)</span> <span class="country">Costa Rica</span><span class="countrySeparator">: </span><span class="drugName">Amlodin raven</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Afiten | Agen | Alozur | Amilostad | Amlodipin | Amlodipin accord | Amlodipin Actavis | Amlodipin aurovitas | Amlodipin bluefish | Amlodipin hbf | Amlodipin mylan | Amlodipin Orion | Amlodipin Teva | Amlodipin vitabalans | Amlopp | Amloratio | Amlozek | Apo amlo | Cardilopin | Hipres | Normodipine | Norvasc | Orcal | Orcal Neo | Recotens | Torella | Zeppeliton | Zorem</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Amlo | Amlo denk | Amlo Q | Amlo Q besilat | Amlo Teva | Amlo wolff | Amlobesilat | Amlobeta mesilat | Amlocard | Amloclair | Amlodigamma top | Amlodipin | Amlodipin (besilat) Dexcel | Amlodipin abz | Amlodipin accedo | Amlodipin Acino | Amlodipin actavis | Amlodipin aurobindo | Amlodipin awd | Amlodipin basics | Amlodipin Besilat Heumann | Amlodipin Corax | Amlodipin dexcel | Amlodipin dura | Amlodipin fair-med | Amlodipin hec pharm | Amlodipin hexal | Amlodipin Ivax | Amlodipin mesilate | Amlodipin puren | Amlodipin q-pharm | Amlodipin Ratiopharm | Amlodipin sandoz | Amlodipin stada | Amlodipin Volkspharma | Amlodipin von ct | Amlodipin Winthrop | Amlolich | Amparo | Norvas | Norvasc | Sigamlo</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Amlodipin 1a farma | Amlodipin actavis | Amlodipin Alpharma | Amlodipin Alternova | Amlodipin Arrow | Amlodipin Copyfarm | Amlodipin Gea | Amlodipin hexal | Amlodipin Pfizer | Amlodipin Ratiopharm | Amlohexal | Amlopharm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Aloten | Amapine | Amlibon | Amloblock | Amlobrit | Amlocardi | Amlocol | Amlodipina | Amlodipina besilat | Amlodipina Lam | Amlodipine | Amlodipino | Amlofel | Amloseven | Amlosyn | Amlovas | Ampliron | Ampres | Amtas | Asomex | Cardicol | Carpin | Corameys | Diasis | Lochem | Lodipar | Lodipin | Lodipres | Maxidipin | Nor-Lodipina | Norvasc | Perten | Premina | Presodip | Stein novopres | Vasocal | Vasonil</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Amdipin | Amlibon | Amlodipina | Amlodipina Mepha | Amlodipino | Amlodipino MK | Amlodipino-R | Amlor | Amlosyn | Amlovid | Ampliron | Cardiopine | Goritel | Lodipar | Noloten | Nordipax | Normapres | Norvasc | Stamlo | Vasocal | Vasodil | Vasonorm | Vasotop | Zidane</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Agen | Amlocard | Amlodipin Ratiopharm | Amlodipine Accord | Amlodipine teva | Amlodipine vitabalans | Hipres | Lofral | Normodipin | Norvasc</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Adcodipine | Alkapress | Amilo | Amlodipine | Amlor | Amlowest | Cardiovasc | Coronavine | Dipotensive | Myodura | Norvasc | Pinavasc | Regcor | Vasonorm | Vasopine | Windipine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Amlodipino | Amlodipino accord | Amlodipino Actavis | Amlodipino Almus | Amlodipino alter | Amlodipino Aphar | Amlodipino Apotex | Amlodipino Aurobindo | Amlodipino aurovitas | Amlodipino bexal | Amlodipino Bluefish | Amlodipino combix | Amlodipino Cuvefar | Amlodipino Korhispana | Amlodipino Lareq | Amlodipino Mabo | Amlodipino Mylan | Amlodipino mylan pharmaceuticals | Amlodipino Normon | Amlodipino pharmacia | Amlodipino Pharmagenus | Amlodipino Ranbaxy | Amlodipino Ratiomed | Amlodipino Ratiopharm | Amlodipino sandoz | Amlodipino Stada | Amlodipino Tarbis | Amlodipino Tecnigen | Amlodipino Teva | Amlodipino ur | Amlodipino vir | Amlodipino vir pharma | Amlodipino winthrop | Arainno | Astudal | Norvas | Zabart</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Amcardia | Amlibon | Amlo denk | Amlocor | Amlodin | Amlodipine | Amlodipine besylate | Amlodipino vir pharma | Amlopin | Amlorine | Amodep | Anlodin | Hovasc | Klodip | Norvasc</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Amlodipin | Amlodipin accord | Amlodipin bluefish | Amlodipin bmm pharma | Amlodipin Enna | Amlodipin generics | Amlodipin hexal | Amlodipin Ivax | Amlodipin krka | Amlodipin Orifarm | Amlodipin Ranbaxy | Amlodipin Ratiopharm | Amlodipine vitabalans | Amlodorion | Amloratio | Norvasc</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Amlodipine | Amlodipine Accord | Amlodipine arrow | Istin</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Amlocad | Amlodose | Amlonova | Lg Amlodac | Randip | Ronamlo</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Agen | Amlibon | Amlodipine | Amlodipine besilate/Teva | Amlotens | Nolvac | Nordex | Normodin | Norvagen</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">A-Phine | Amdocal | Amedin | Amlocor | Amlodigamma | Amlodipina Farmoz | Amlodipine gp | Amlodipine sandoz | Amlodipine teva | Amlong | Amlopin | Amlorine | Amlotens | Amlozen | Amodep | Amtas | Apo amlodipine | Cp lovac | Emlip | Hovasc | Lofral | Lomakline | Lopicard | Norvasc | Pms Amlodipine | Stadovas | Zynor</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Almirin | Amlodipin Cipla | Amlodipin Genera | Amlodipin Genericon | Amlodipin PharmaS | Amlodipin sandoz | Amlopin | Amonex | Caprez | Doremis | Lopin | Norvasc | Tenox | Vilpin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Alozur | Amlipin | Amlobesyl | Amlodep | Amlodipin bezilat ratiopharm | Amlodipin mylan | Amlodipin Pharma Regist | Amlodipin pharma vim | Amlodipin Ratiopharm | Amlodipin Teva | Amlodipin vitabalans | Amlodipress 1 A Pharma | Amlozek | Cardilopin | Normodipine | Norvasc | Tenox</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">A B Vask | Amcor | Amdixal | Amlocor | Amlodipine | Amlodipine besylate | Amlodipine besylate 10 | Amlogal | Amlogrix | Amloten | Belvas | Bufacardo | Calsivas | Comdipin | Corvask | Cydipin | Dilavask | Divask | Ethivask | Finevask | Fulopin | Gensia | Gracivask | Gravask | Intervask | Licodipin | Lodipas | Lovask | Norvask | Opivask | Pehavask | Provask | Samcovask | Sandovask | Simvask | Stamotens | Tensivask | Vasgard | Zenicardo | Zevask</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Amlist | Amlodipine | Amlodipine bluefish | Amlodipine teva | Istin | Istolde</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Amlow | Norvasc</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aamin | Acord | Adipin | Adipine | Adp | Aginal | Aglodepin | Am-5 | Amaday | Amanat | Amcard | Amchek | Amdac | Amdepin | Amfirst | Amicardia | Amilip | Amizac | Amlan | Amlan s | Amleod | Amlibon | Amlin | Amlip | Amlo | Amloc | Amlocom | Amlocor | Amlod | Amlodac | Amlodipin aaa | Amlogard | Amlogen | Amlogold | Amloheart | Amlokath | Amlokind | Amlokos | Amlol | Amlomed | Amlona | Amlong | Amlopar | Amlopin | Amlopres | Amlopure | Amlosafe | Amlostat | Amlosun | Amlosyl | Amlot | Amlotrust | Amlotus | Amlovas | Amlovas-S | Amlovel | Amlovib | Amlovin | Amloz | Amo | Amodep | Ampin | Ampine | Amrap | Amsach | Amsure | Amtas | Amvasc | Amvio | Amwa | Amzak o.d. | Angicam | Angiguard | Asomex | Avacard | Bamlo | Big dur | Biodipin | Bp Mide | Calchek | Camlek | Camlo | Camlodip | Card | Carvasc | Ccb | Corvadil | Defidin | Diavasc | Dip | Elpress | Emadine | Esam | Esamlo | Esamlovin | Esdil | Eslo | Espin | Klodip | Lama | Lodipin | Lopin | Lupidip | M l o | Malodip | Milopin | Myodura | Nipidol | Numlo | Primodil | Redipil | S ampure | S-Camlo | S-klodip | Samlodon | Samlokind | Samstar | Sitelodip | Stamlo | Stressban | Tamlod | Topdip | Truamil | Udp | Vamlo | Wellamo</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Amlodepen | Awalodipin | Samadipine</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Amlo</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Abis | Almidis | Amlodipina | Amlodipina acc | Amlodipina almus | Amlodipina Arrow | Amlodipina aurobindo | Amlodipina Awp | Amlodipina Bluefish | Amlodipina Doc | Amlodipina Doc Generici | Amlodipina EG | Amlodipina pharmeg | Amlodipina Sandoz | Amlodipina teva italia | Amlodipina zentiva | Amlonor | Amlopol | Antacal | Aristamid | Balarm | Krudipin | Losedin | Monopina | Natam | Norvasc | Pressac | Tensilene</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Amlocard | Amlovas | Diplow | Lofral | Lowvasc | Vaznor</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Amlodin | Amlodipine | Amlodipine kyorin | Amlodipine NS | Amlodipine od tyk | Amlodipine Ohara | Amlodipine Towa | Amlodipine tsuruhara | Norvasc</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Adipin | Amax | Amdip | Amdocal | Amedin | Amlibon | Amlo denk | Amloas | Amlocare | Amlocian | Amlocip | Amlodawa | Amlodeal | Amlodin | Amlodine | Amlodip | Amlofine | Amlomark | Amlong | Amlopres | Amlosafe | Amlosin | Amlostar | Amlosun | Amlovas | Amlozest | Amolab | Amtas | Asomex | Camlodin | Esam | Eslo | Flamodip | Gencard | Kardam | Lofral | Norvasc | Primodil | Provask | Stamlo | Swamlo | Varinil | Vazkor</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">A dipine | A pine | Alonorva | Am | Ambes | Ambiz | Ambp | Amlo one | Amlobepine | Amlobesyl | Amlobetine | Amlobis | Amlocan | Amlocard | Amlock | Amloda | Amlodapine | Amlodi | Amlodigen | Amlodin | Amlodip | Amlodipine | Amlodipine huons | Amlodown | Amloem | Amlogood | Amloke | Amlol | Amlomax | Amlomesil | Amlomin | Amlonin | Amlopin | Amloril | Amlosk | Amlospin | Amlospine | Amlost | Amlostar | Amlosyl | Amloten | Amlova | Amnodin | Amodin | Amodipin | Amodipin s | Amopin | Amopine | Amotension | Ampibesyl | Ampidipine | Amrokan | Amvesc | Anitin | Anopine | Anydipine | Anytension | Anytin | Ard | Arodioin | Arodip | Aropin | Asyldopine | Aukodifin | Barodipine | Bc low | Beardipine S | Belopin | Berodipin | Besandropin | Besdipine | Besylopine | Calblock | Calbroc | Cmg Amlodipine | Cobisk | D.w amlodipine besylate | Daewoongbio amlodipine | Davidipine | Diadin | Diroba | Dirova | Dongsung amlodipine | Dongwha amlodipine besylate | E dipine | Easytension | Emdipin | Empidipine | Enydipine | Eudipine | Evasc | Everdipine | Finedipine | Haperten | Harodin | Huniz amlodipine maleate | Ilvasc | J dipine | Kranos | Kukje amlodipine | Lopin | Loudipine | Lovasc | Lowdin | M lodipine | Medipin | Medipine | Melodipine | MyungMoon Amlodipine | Navanel | Neodropine | Neurophin | New amlodip | Newadin | Newdipin | Newsc | Newsdipine | Normaloc | Norvac | Norvaforce | Norvaloc | Norvasc | Norvatec | Nosk | Novacadin | Novacot | Novadic | Novadipin | Novagen | Novalopine | Novamopine | Novapin | Novascan | Novasphin | Novastin | Novatec | Novatension | Novatin | Novcapine | Novdipine | Octadipine | Orodipine | Prestin | Prodipine | Sandoz amlodipine | Selodipine | Seoul amlodipine besylate | Siamlopin | Sinnovapin | Skad | Skad b | Stadipin | Stardipine | Taiguk amlodipine | TDS Amlodipine Besylate | Unasc | Unibesyl | Uniropin | Urodipine | Varodipine | Varosc | Wydipine | Yungjin amlodipine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Amlo | Amlocim | Amlozek | Amvaz | Istin | Lofral | Vascodipine</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Amdip | Amline | Amlo | Amlocard | Amlocim | Amlodipin Genericon | Amlodipine | Amlogal Divule | Amlorine | Amosarc | Cinopin | Torans</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Agen | Alneta | Amlocard | Amlodipin Medochemie | Amlodipin Teva | Amlodipine Accord | Amlodipine Ingen Pharma | Amlodipine vitabalans | Emlodin | Normodipine | Norvasc | Orkal | Stamlo | Tenox</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Amlodipine Besilaat Sandoz</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Agen | Amlocard | Amlodigamma | Amlodipin Medochemie | Amlodipin Olainfarm | Amlodipin Ratiopharm | Amlodipin Teva | Amlodipine Accord | Amlodipine vitabalans | Norvasc | Tenox</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Amep | Amilo | Amlodipine | Amlodipine gt | Amlor | Amovas | Anglor | Calcinib | Dipicor | Dolpine | Inikal | Lorcard | Medep | Olmadip | Perovasc | Pimlo</span>;</li>
<li>
<span class="countryCode">(MT)</span> <span class="country">Malta</span><span class="countrySeparator">: </span><span class="drugName">Vasorex</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Adiuvo | Aken | Aldromasil | Ambel tec | Amlibon | Amlibon bes | Amlodipino | Amlodipino genetica | Amlodipino landsteiner | Amlodipino liomont | Amlodipino raam | Amtev | Angiodal | Apodino | Calantago | Cantry | Cardecal | Ccbcard | Collidipin | Cropinex | Eslodinepin | Invical | Juvalid | Lalpro | Lodicar | Lodicord | Nablody | Nordiver | Norpled | Norvas | Pequisy | Poltroon | Preslopin | Presone 1 | SBL Car | Sistopres | Spinodin | Stamlomex | Torlo | Tropad | Zadivonal | Zagapsol | Zaxinat</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Amcardia | Amcor | Amdepin | Amkline | Amlibon | Amlodac | Amlomed | Amlong | Amlopin | Amlopres | Amnoz | Amod | Amtas | Anlodin | Avevasc | Camlodin | Kardam | Lofral | Nordipine | Norvasc | Nulop | Primodil | Stadovas | Sunvasc | Tenox | Vamlo | Zynor</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Acedipin | Amcard | Amdepin | Amdocal | Amilod | Amlo | Amlodipine | Amlodipine besylate | Amloditop | Amloedge | Amloheal | Amlokris | Amlomed | Amlopril | Amlosam | Amlozest | Amnique | Ampine | Amzak | Anlodin | Asomex | Baropin | Bg vascol | Bpcon | Cadiprot | Chiram | Cladipine | Danlodip | Deno amlodipine | Dilopax | Diplovas | Dovipine | Eden | Eden amlodipine | Emzovasc | Esam | Everdestiny amlodipine | Glopam | Hevasc | Jaffkin amlodipine | Juvasc | K amlod | Lalit | Lopin | Maclodipine | Meem amlodipine | Miravasc | Nci amlodipine | Nelb amlodipine | Norvasc | Novaday | P one amlodipine | Pectovasc | Pemalod | Pharmamax amlodipine | Pilovas | Relodipin | Ritedipine | Ronybo amlodipine | Rotadipine | Rumapine | Swamlo | Tevasc | Triumvirate amlodipine | V bells amlodipine | Zyropin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Amlodipine | Amlodipine (als besilaat) sandoz | Amlodipine A | Amlodipine Actavis | Amlodipine aurobindo | Amlodipine bluefish | Amlodipine CF | Amlodipine sandoz | Norvas | Norvasc</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Amlodipin | Amlodipin accord | Amlodipin actavis | Amlodipin bmm pharma | Amlodipin Copyfarm | Amlodipin hexal | Amlodipin Hexal | Amlodipin sandoz | Amlodipine vitabalans | Istin | Norvasc</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo amlodipine | Calvasc | Norvasc | Vasorex</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Vascodipine</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Alestol | Amdipin | Amidile g | Amlobiotech | Amlocar | Amlodipino | Amlodipress | Amlong | Amloprednil | Amlovas | Calchek | Coropine | Edemsoft | Finacal | Noloten | Norvasc | Olutan | Stamlo | Tensocard | Ximax</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Acipta | Actapin | Aforbes | Alodine | Amaday | Amalvex | Ambesyl | Ambloc | Amdipine | Amilip | Amlion | Amlix | Amlobes | Amlocare | Amlocor | Amlodac | Amlodia | Amlodipine | Amlodipine Ritemed | Amlogen | Amlogin | Amlokard | Amlonex | Amlong | Amlopin | Amlopure | Amlorex | Amloric | Amlorika | Amlosyl | Amlothix | Amlotraz | Amlotrene | Amnique | Amnor | Amo | Amvalat | Amvasc BE | Angivasc | Aprenorm | Arcadia | Besilopin | Besylon | Bezam | Blocapast | Boie amlodipine besilate | Calbloc | Calcebis | Calcheck | Calvaso | Cardiovasc | Cardivasc | Cardol | Coram | Corvex | Covasc | Dailyvasc | Danlopin | Derox | Dilavasc | Emlip | Eodipine | Eurovasc | Exeldin | Godipine | Hartvasc | Hylodine | Hyperta | Johnvasc | Lodibes | Lodibiz | Lodicap | Lodicor | Lodipen | Lodiper | Lodipex | Medipin | Medivasc | Morvas | Nepidol | Norbloc | Norvac | Norvasc | Norvatrol | Odasyl | Omnivas | Philvasc | Prelod | Proamlo | Prodipine | Provasc | Rhea Amlodipine | Sainyo | Scilodipine | Sedipin | Swamlo | Sylodipine | Teneze | Varodipine | Vasalat | Vascar | Vaselec | Vaselon | Vasocar | Vasprim | Wilomax</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Adoptin | Alopine | Amdipine | Amdocal | Amdol | Amepine | Amilip | Aml | Amlis | Amlobest | Amlocard | Amlod | Amlodip | Amlonext | Amlopin | Amlosyd | Amlotac | Amlow | Amodip | Amolin | Ampress | Amrx | Anam | Angipin | Bescard | Ca-B | Cabok | Calbor | Caloc | Canta | Caprinza | Cardiosil | Cardiovasc | Coram | Corcont | Cordium | Corinor | Corsafe | Dipsan | Ephacard | G-sac | Hartvasc plus | Hodip | Hypercor | Hypernil | Hypotin | Hypress | Istin | Leaf | Lodipin | Lodopin | M Low | Medvasc | Megadip | Melody | Melopen | Miforec | Miosil | Modopine | Neopres | Norsap 5 | Norvasc | Onato | Pidol | Prescard | Quvasc | Ravapine | Revloc | Rydem | Salome | Securin | Sofvasc | Swint | Vaslopine | Vasodil | Vespin | Zamlo | Zeglopin | Zodip</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Adipine | Agen | Aldan | Almiden | Alneta | Amlaxopin | Amlodipine Aurobindo | Amlodipine Aurovitas | Amlodipine bluefish | Amlodipine Orion | Amlodipine teva | Amlodipine vitabalans | Amlodipinum Tad | Amlomyl | Amlonor | Amlopin | Amloratio | Amlozek | Apo amlo | Cardilopin | Damloc | Finamlox | Normodipine | Norvasc | Tenox | Vilpin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Amlodipine besylate | Katerzia | Norvasc</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Amlocor | Amlodipina | Amlodipina alter | Amlodipina aurobindo | Amlodipina aurovitas | Amlodipina basi | Amlodipina ciclum | Amlodipina Krka | Amlodipina Mibral | Amlodipina mylan | Amlodipina Parke-Davis | Amlodipina Ratiopharm | Amlodipina stada | Amlodipina zentiva | Cardionox | Drime | Mibral | Norvasc | Resines | Tensiovas</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Amlodipina cellofarm | Amlodipina dallas | Amlodipina dutriec | Amlodipina emcure | Amlodipina fda | Amlodipina rospaw | Amlodipino genfar | Amlodipino la sante | Amlodipino mintlab | Amlodipino sanderson | Amlodipino sandoz | Ampliron | Amze | Asomex | Besilato de amlodipino bioethic pharma | Cardiotonil | Corolar | Cuorexam | Hypoten | Inhical | Inihical | Lodinest | Lodipina | Noloten | Normopas | Normoten | Solen | Tensiocom | Terloc | Xaterol | Xaterol forte</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Amlo | Amlocor | Amlodar | Amlogaran | Amopress | Amvasc | Duactin | Glodip | Hypodipine | Lotense | Lowrac | Lowvasc | Norvasc | Qvasc | Vascodipine</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Almacor | Almiden | Alozur | Amlo tad | Amlodigamma | Amlodipin al | Amlodipin vim spectrum | Amlodipina actavis | Amlodipina aurobindo | Amlodipina helcor | Amlodipina lph | Amlodipina terapia | Amlodipina zentiva | Amlodipine | Amlodipine medochemie | Amlodipine valeant | Amlohexal | Cardilopin | Eplodin | Norvasc | Recotens | Tardip | Tenox</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Agen | Akridipin | Amlo | Amlodac | Amlodigamma | Amlodipharm | Amlodipin | Amlodipin agio | Amlodipin Cardio | Amlodipin Teva | Amlodipin Zentiva | Amlodipin zt | Amlodipine | Amlodipine agio | Amlodipine Alkaloid | Amlodipine alsi | Amlodipine besilat | Amlodipine biocom | Amlodipine borimed | Amlodipine Chaika Pharma | Amlodipine prana | Amlodipine reneval | Amlodipine sandoz | Amlodipine sanofi | Amlodipine teva | Amlodipine vertex | Amlodipine zentiva | Amlodipine zt | Amlodipine ZT | Amlodivel | Amlokard sanovel | Amlong | Amlonorm | Amlorus | Amlotop | Amlovas | Calchek | Cardilopin | Cordi cor | Cordy cor | Corvadil | Escordi cor | Karmagip | Normodipine | Normodivask | Norvadin | Norvasc | Omelar cardio | Stamlo | Stamlo M | Tenox | Vero amlodipine</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Amep | Amlocard | Lodipam | Vascodipine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Amlarrow | Amlodipin accord | Amlodipin actavis | Amlodipin aurobindo | Amlodipin bluefish | Amlodipin bmm pharma | Amlodipin jubilant | Amlodipin krka | Amlodipin medical valley | Amlodipin Merck NM | Amlodipin mylan | Amlodipin orifarm | Amlodipin sandoz | Amlodipin stada | Amlodipine teva | Amlodipine vitabalans | Amlodistad | Amloratio | Amlori | Norvasc</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Actapin | Amcardia | Amdhapine | Amlodipine sandoz | Amlong | Amlotens | Amtas | Anlodin | Apo amlodipine | Avevasc | Lodipin | Norvasc | Sunvasc | Swamlo | Tenox | Varodipine | Zynor</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Amlodipin Lek | Amlodipin Teva | Amlodipin vitabalans | Amlodipine | Amlopin | Norvasc | Tenox | Vilpin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Agen | Amlodipin | Amlodipin Actavis | Amlodipin hbf | Amlodipin Orion | Amlodipin sandoz | Amlodipin vitabalans | Amlodipine bluefish | Amlopin | Amlozek | Apresa | Cardilopin | Genam | Normodipine | Norvasc | Tenox | Zamlodax</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Amlodipine</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Ambes | Amcardia | Amloc | Amlodac | Amlopine | Amlopress | Amvas | Deten | Lovas | Narvin | Norvasc</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Amlodep | Amlodipine medis | Amlodipine winthrop | Amlodis | Amlor | Lodepine | Lodipex | Mibral</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Amlodis | Amlohex | Amlokard | Amlovas | As Amlo | Dilopin | Lipinox | Modipin | Monovas | Nipidol | Norlopin | Normopres | Norvadin | Norvasc | Penvasc | Vasocard | Vazkor</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Alopine | Amcopine | Amilo | Amlo | Amlobin | Amlodac | Amlodine | Amlodipine | Amlodipine sandoz | Amlos | Amlosin | Amndiline | Amopine | Calnelpress | Cinopin | Cinsuton | Du.Q | Lodipine | Lolate | Nobar | Nordipine | Norvasc | Taishunmai | Yawaho</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Agen | Aladin | Amlo | Amlocim | Amlocor | Amlodex | Amlodin | Amlodipin | Amlodipin darnitsa | Amlodipin kv | Amlodipine | Amlodipine euro | Amlodipine pfizer | Amlodipine sandoz | Amlodipine teva | Amlokard sanovel | Amlong | Amlopin | Amlopril | Amlosandoz | Amlovas | Amlovel | Emlodin | Normodipin | Norvasc | Semlopin | Stamlo | Vasodipin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Amlibon | Amlo denk | Amlo h | Amloas | Amlong | Amlopress | Amlotrust | Amlovas | Amtas | Anlodin | Asomex | Cardiosan | Cardipac | Coram | Corvadil | Derox | Kardam | Primodil | Vazkor</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Amlodipina | Amlodipina Ivax | Amlodipina regueiro | Amlodipino sandoz | Amlopress | Ampliron | Amxel | Angiostabil | Cordiax | Ilduc | Norvasc | Tensofin | Terloc</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ambiodipina | Amipina | Amlibon | Amloc | Amlodipina | Amlodipino | Amlopin | Amlovas | Amval | Angiovan | Cab | Carpin | Dilotex | Lodipin | Medlo | Nilam | Norvasc | Pinam | Stamlo | Unidoscor | Vasocal</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Amloboston | Amlodipin Domesco | Amlothope | Bluepine | Cardivasor | Lodimax | Pymealong</span>;</li>
<li>
<span class="countryCode">(YE)</span> <span class="country">Yemen</span><span class="countrySeparator">: </span><span class="drugName">Amlodak</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco norpene | Almadin | Amlate | Amloc | Amlodipine biotech | Amlodipine unicorn | Amlodipine unimed | Amlodipine Winthrop | Amtas | Aprate | Austell amlodipine | Ciplavasc | Corvadil | Cpl alliance amlodipine | Gulf amlodipine | Indo amlodipine | Keysal | Klodip | Lomanor | Norcard | Nortwin | Norvasc | Pendine | Sandoz amlodipine | Stamlo</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Amdepin | Amlo denk | Amlo h | Amlodac | Amlodipine | Amlovas | Amlowin | Amlox | Amtas | Asomex | Corvadil | Esam | Flamodip | Kardam | Klodip | Lomanor | Norvasc | Primodil | Varinil</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Amlin | Amlo h | Amlocor | Amlopres | Amlovar | Amlovasc | Corvadil | Lomanor | Norvasc</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17469008">
<a name="17469008"></a>Ahn HK, Nava-Ocampo AA, Han JY, et al, "Exposure to Amlodipine in the First Trimester of Pregnancy and During Breastfeeding," <i>Hypertens Pregnancy</i>, 2007, 26(2):179-87. doi:10.1080/10641950701204554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/17469008/pubmed" id="17469008" target="_blank">17469008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 203: chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50. doi:10.1097/AOG.0000000000003020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16772760">
<a name="16772760"></a>Andersen J, Groshong T, Tobias JD. Preliminary experience with amlodipine in the pediatric population. <i>Am J Ther</i>. 2006;13(3):198-204. doi:10.1097/01.mjt.0000147593.73888.d5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/16772760/pubmed" id="16772760" target="_blank">16772760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi: 10.1002/cpt.377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30265578">
<a name="30265578"></a>Aoki H, Ito N, Kaniwa N, et al. Low levels of amlodipine in breast milk and plasma. <i>Breastfeed Med</i>. 2018;13(9):622-626.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/30265578/pubmed" id="30265578" target="_blank">30265578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33277458">
<a name="33277458"></a>Arasan SN, Yenigun EC, Cevher SK, Dede F. Amlodipine induced massive ascites, a rare clinical case. <i>Iran J Kidney Dis.</i> 2020;14(6):517-519.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/33277458/pubmed" id="33277458" target="_blank">33277458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21518977">
<a name="21518977"></a>Aronow WS, Fleg JL, Pepine CJ, et al, “ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,” <i>Circulation</i>, 2011, 123(21):2434-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/21518977/pubmed" id="21518977" target="_blank">21518977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21772148">
<a name="21772148"></a>Baetz BE, Patton ML, Guilday RE, Reigart CL, Ackerman BH. Amlodipine-induced toxic epidermal necrolysis. <i>J Burn Care Res</i>. 2011;32(5):e158-e160. doi:10.1097/BCR.0b013e31822ac7be<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/21772148/pubmed" id="21772148" target="_blank">21772148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28895508">
<a name="28895508"></a>Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. <i>Vasa</i>. 2017;46(6):413-423. doi: 10.1024/0301-1526/a000661.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/28895508/pubmed" id="28895508" target="_blank">28895508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10412882">
<a name="10412882"></a>Biston P, Mélot C, Degaute JP, et al. Prolonged antihypertensive effect of amlodipine: a prospective double-blind randomized study. <i>Blood Press</i>. 1999;8(1):43-48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/10412882/pubmed" id="10412882" target="_blank">10412882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14965638">
<a name="14965638"></a>Cornes PG, Hole AC. Amlodipine gynaecomastia. <i>Breast</i>. 2001;10(6):544-545. doi:10.1054/brst.2001.0308<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/14965638/pubmed" id="14965638" target="_blank">14965638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23442182">
<a name="23442182"></a>Cvetković Z, Suvajdžić-Vuković N, Todorović Z, Panić M, Nešković A. Simvastatin and amlodipine induced thrombocytopenia in the same patient: double trouble and a literature review. <i>J Clin Pharm Ther</i>. 2013;38(3):246-248. doi:10.1111/jcpt.12051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/23442182/pubmed" id="23442182" target="_blank">23442182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24592551">
<a name="24592551"></a>Demirci H, Polat Z, Kantarcioglu M, Kekilli M, Uygun A, Bagci S. Short-term amlodipine induced liver injury : an extremely rare acute complication. <i>Acta Gastroenterol Belg</i>. 2013;76(4):441.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/24592551/pubmed" id="24592551" target="_blank">24592551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8375125">
<a name="8375125"></a>Donnelly R, Meredith PA, Miller SH, et al. Pharmacodynamic modeling of the antihypertensive response to amlodipine. <i>Clin Pharmacol Ther</i>. 1993;54(3):303-310.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/8375125/pubmed" id="8375125" target="_blank">8375125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2524389">
<a name="2524389"></a>Doyle GD, Donohue J, Carmody M, Laher M, Greb H, Volz M. Pharmacokinetics of amlodipine in renal impairment. <i>Eur J Clin Pharmacol</i>. 1989;36(2):205-208.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/2524389/pubmed" id="2524389" target="_blank">2524389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24169926">
<a name="24169926"></a>Dressler D. Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine. <i>J Neural Transm (Vienna)</i>. 2014;121(4):367-369. doi:10.1007/s00702-013-1108-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/24169926/pubmed" id="24169926" target="_blank">24169926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Egbuonu.1">
<a name="Egbuonu.1"></a>Egbuonu F, Zazal B, Atwan M, Davies A. Rare case of amlodipine induced hepatitis: a case report. <i>J Med Therap. </i>2019;3:1-2.doi:10.15761/JMT.1000142</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10940749">
<a name="10940749"></a>Ejaz AA, Fitzpatrick PM, Haley WE, Wasiluk A, Durkin AJ, Zachariah PK. Amlodipine besylate induced acute interstitial nephritis. <i>Nephron</i>. 2000;85(4):354-356.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/10940749/pubmed" id="10940749" target="_blank">10940749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al; American College of Cardiology Foundation/American Heart Association Task Force. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons [published correction appears in <i>Circulation</i>. 2014;129(16):e463]. <i>Circulation</i>. 2012;126(25):e354-e471. doi: 10.1161/CIR.0b013e318277d6a0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28827377">
<a name="28827377"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2017;140(3).<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/28827377/pubmed" id="28827377" target="_blank">28827377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11149130">
<a name="11149130"></a>Flynn JT and Pasko DA, “Calcium Channel Blockers: Pharmacology and Place in Therapy of Pediatric Hypertension,” <i>Pediatr Nephrol</i>, 2000, 15(3-4):302-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/11149130/pubmed" id="11149130" target="_blank">11149130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16855075">
<a name="16855075"></a>Flynn JT, Nahata MC, Mahan JD Jr, Portman RJ; PATH-2 Investigators. Population pharmacokinetics of amlodipine in hypertensive children and adolescents. <i>J Clin Pharmacol</i>. 2006;46(8):905-916.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/16855075/pubmed" id="16855075" target="_blank">16855075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15343191">
<a name="15343191"></a>Flynn JT, Newburger JW, Daniels SR, et al, "A Randomized, Placebo-Controlled Trial of Amlodipine in Children With Hypertension," <i>J Pediatr</i>, 2004, 145(3):353-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/15343191/pubmed" id="15343191" target="_blank">15343191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11041159">
<a name="11041159"></a>Flynn JT, Smoyer WE, and Bunchman TE, “Treatment of Hypertensive Children With Amlodipine,” <i>Am J Hypertens</i>, 2000a, 13(10):1061-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/11041159/pubmed" id="11041159" target="_blank">11041159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19797310">
<a name="19797310"></a>Gargh K, Baildam EM, Cleary GA, Beresford MW, McCann LJ. A retrospective clinical analysis of pharmacological modalities used for symptomatic relief of Raynaud's phenomenon in children treated in a UK paediatric rheumatology centre. <i>Rheumatology (Oxford)</i>. 2010;49(1):193‐194.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/19797310/pubmed" id="19797310" target="_blank">19797310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35165595">
<a name="35165595"></a>Gouveia R, Veiga H, Costa AA, Pereira J, Lourenço P. Bradycardia, renal failure, atrioventricular nodal blockade, shock, and hyperkalemia syndrome due to amlodipine: a case report of an underdiagnosed medical condition. <i>Cureus</i>. 2022;14(1):e21144. doi:10.7759/cureus.21144.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/35165595/pubmed" id="35165595" target="_blank">35165595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25239629">
<a name="25239629"></a>Hammerstrom AE. Possible amlodipine-induced hepatotoxicity after stem cell transplant. <i>Ann Pharmacother</i>. 2015;49(1):135-139. doi:10.1177/1060028014552820<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/25239629/pubmed" id="25239629" target="_blank">25239629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women [published correction appears in <i>N Engl J Med</i>. 2000;343(18):1348]. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19052124">
<a name="19052124"></a>Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. <i>N Engl J Med</i>. 2008;359(23):2417-2428. doi: 10.1056/NEJMoa0806182.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/19052124/pubmed" id="19052124" target="_blank">19052124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32099704">
<a name="32099704"></a>John K, Mishra AK, Gunasekaran K, Iyyadurai R. Amlodipine-induced gingival hyperplasia in a young male with stage 5 chronic kidney disease. <i>Case Rep Nephrol</i>. 2020;7801546. doi:10.1155/2020/7801546.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/32099704/pubmed" id="32099704" target="_blank">32099704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8911887">
<a name="8911887"></a>Josefsson M, Zackrisson AL, and Ahlner J, “Effect of Grapefruit Juice on the Pharmacokinetics of Amlodipine in Healthy Volunteers,” <i>Eur J Clin Pharmacol</i>, 1996, 51(2):189-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/8911887/pubmed" id="8911887" target="_blank">8911887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Katerzia.1">
<a name="Katerzia.1"></a>Katerzia (amlodipine) [prescribing information]. Wilmington, MA: Azurity Pharmaceuticals Inc; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Katerzia.2">
<a name="Katerzia.2"></a>Katerzia suspension (amlodipine) [prescribing information]. Greenwood Village, CO: Silvergate Pharmaceuticals, Inc; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9475697">
<a name="9475697"></a>Khattak S, Rogan JW, Saunders EF, et al, “Efficacy of Amlodipine in Pediatric Bone Marrow Transplant Patients,” <i>Clin Pediatr (Phila)</i>, 1998, 37(1):31-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/9475697/pubmed" id="9475697" target="_blank">9475697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33637192">
<a name="33637192"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease.<i> Kidney Int.</i> 2021;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/33637192/pubmed" id="33637192" target="_blank">33637192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27941129">
<a name="27941129"></a>Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Ann Rheum Dis</i>. 2017;76(8):1327‐1339.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/27941129/pubmed" id="27941129" target="_blank">27941129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12845505">
<a name="12845505"></a>Kungys G, Naujoks H, Wanner C. Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. <i>Eur J Clin Pharmacol</i>. 2003;59(4):291-295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/12845505/pubmed" id="12845505" target="_blank">12845505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10950093">
<a name="10950093"></a>Lafuente NG. Calcium channel blockers and hepatotoxicity. <i>Am J Gastroenterol</i>. 2000;95(8):2145. doi:10.1111/j.1572-0241.2000.02223.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/10950093/pubmed" id="10950093" target="_blank">10950093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline No. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management.<i> J Obstet Gynaecol Can.</i> 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21558959">
<a name="21558959"></a>Makani H, Bangalore S, Romero J, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials. <i>J Hypertens</i>. 2011;29(7):1270-1280. doi:10.1097/HJH.0b013e3283472643<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/21558959/pubmed" id="21558959" target="_blank">21558959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.1">
<a name="Mann.1"></a>Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1532771">
<a name="1532771"></a>Meredith PA and Elliott HL, "Clinical Pharmacokinetics of Amlodipine," <i>Clin Pharmacokinet</i>, 1992, 22(1):22-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/1532771/pubmed" id="1532771" target="_blank">1532771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35496508">
<a name="35496508"></a>Mizuta T, Kato M. Amlodipine-induced subacute cutaneous lupus erythematosus localized to non-sun-exposed areas. <i>Case Rep Dermatol.</i> 2022;14(1):71-76. doi:10.1159/000524001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/35496508/pubmed" id="35496508" target="_blank">35496508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29523279">
<a name="29523279"></a>Morgan JL, Kogutt BK, Meek C, et al. Pharmacokinetics of amlodipine besylate at delivery and during lactation. <i>Pregnancy Hypertens</i>. 2018;11:77-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/29523279/pubmed" id="29523279" target="_blank">29523279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Morgan.1">
<a name="Morgan.1"></a>Morgan JL, Kogutt BK, Meek C et al. Pharmacokinetics of amlodipine besylate during pregnancy-how much infant exposure occurs? <i>Am J Obstet Gynecol</i>. 2017;216:S515-S516.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17873487">
<a name="17873487"></a>Nahapetian A, Oudiz RJ. Serial hemodynamics and complications of pregnancy in severe pulmonary arterial hypertension. <i>Cardiology</i>. 2008;109(4):237-240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/17873487/pubmed" id="17873487" target="_blank">17873487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25447596">
<a name="25447596"></a>Naito T, Kubono N, Deguchi S, et al. Amlodipine passage into breast milk in lactating women with pregnancy-induced hypertension and its estimation of infant risk for breastfeeding. <i>J Hum Lact</i>. 2015a;31(2):301-306. doi: 10.1177/0890334414560195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/25447596/pubmed" id="25447596" target="_blank">25447596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26654672">
<a name="26654672"></a>Naito T, Kubono N, Ishida T, et al. CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine. <i>Drug Metab Pharmacokinet</i>. 2015b;30(6):419-424. doi: 10.1016/j.dmpk.2015.08.008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/26654672/pubmed" id="26654672" target="_blank">26654672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHLBI.1">
<a name="NHLBI.1"></a>National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, Clinical Practice Guidelines, 2011, National Institutes of Health. Available at <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf%20" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf </a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, "The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents," <i>Pediatrics</i>, 2004, 114(2 Suppl 4th Report):555-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. NICE guideline, No. 133. http://www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Norliqva.1">
<a name="Norliqva.1"></a>Norliqva (amlodipine) [prescribing information]. Farmville, NC: CMP Pharma Inc; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Norvasc.1">
<a name="Norvasc.1"></a>Norvasc (amlodipine) [prescribing information]. New York, NY: Pfizer Labs; January 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Norvasc.2">
<a name="Norvasc.2"></a>Norvasc (amlodipine) [product monograph]. Kirkland, Quebec, Canada: Upjohn Canada ULC; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33229116">
<a name="33229116"></a>Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/33229116/pubmed" id="33229116" target="_blank">33229116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24621933">
<a name="24621933"></a>Packer M, Carson P, Elkayam U, et al; PRAISE-2 Study Group. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). <i>JACC Heart Fail</i>. 2013;1(4):308-314. doi: 10.1016/j.jchf.2013.04.004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/24621933/pubmed" id="24621933" target="_blank">24621933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8813041">
<a name="8813041"></a>Packer M, O'Connor CM, Ghali JK, et al, “Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure. Prospective Randomized Amlodipine Survival Evaluation Study Group,” <i>N Engl J Med</i>, 1996, 335(15):1107-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/8813041/pubmed" id="8813041" target="_blank">8813041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11833502">
<a name="11833502"></a>Parker ML, Robinson RF, and Nahata MC, “Amlodipine Therapy in Pediatric Patients With Hypertension,” <i>J Am Pharm Assoc</i>, 2002, 42(1):114-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/11833502/pubmed" id="11833502" target="_blank">11833502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-pdp-Amlodipine.1">
<a name="pdp-Amlodipine.1"></a>pdp-Amlodipine [product monograph]. Montreal, Quebec, Canada: Pendopharm, Division of Pharmascience Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11464254">
<a name="11464254"></a>Pedrinelli R, Dell'Omo G, Mariani M. Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension. <i>J Hum Hypertens</i>. 2001;15(7):455-461. doi:10.1038/sj.jhh.1001201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/11464254/pubmed" id="11464254" target="_blank">11464254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10679507">
<a name="10679507"></a>Pedrinelli R, Dell'Omo G, Melillo E, Mariani M. Amlodipine, enalapril, and dependent leg edema in essential hypertension. <i>Hypertension</i>. 2000;35(2):621-625. doi:10.1161/01.hyp.35.2.621<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/10679507/pubmed" id="10679507" target="_blank">10679507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9727842">
<a name="9727842"></a>Pfammatter JP, Clericetti-Affolter C, Truttmann AC, et al, “Amlodipine Once-Daily in Systemic Hypertension,” <i>Eur J Pediatr</i>, 1998, 157(8):618-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/9727842/pubmed" id="9727842" target="_blank">9727842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11045391">
<a name="11045391"></a>Rogan JW, Lyszkiewicz DA, Blowey D, et al, “A Randomized Prospective Crossover Trial of Amlodipine in Pediatric Hypertension,” <i>Pediatr Nephrol</i>, 2000, 14(12):1083-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/11045391/pubmed" id="11045391" target="_blank">11045391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26256559">
<a name="26256559"></a>Schetz D, Kocić I. A new adverse drug reaction--Schamberg's disease caused by amlodipine administration--a case report. <i>Br J Clin Pharmacol</i>. 2015;80(6):1477-1478. doi:10.1111/bcp.12742<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/26256559/pubmed" id="26256559" target="_blank">26256559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9126675">
<a name="9126675"></a>Scholz H. Pharmacological aspects of calcium channel blockers. <i>Cardiovasc Drugs Ther</i>. 1997;10:869-872.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/9126675/pubmed" id="9126675" target="_blank">9126675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10562973">
<a name="10562973"></a>Silverstein DM, Palmer J, Baluarte HJ, et al, “Use of Calcium-Channel Blockers in Pediatric Renal Transplant Recipients,” <i>Pediatr Transplant</i>, 1999, 3(4):288-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/10562973/pubmed" id="10562973" target="_blank">10562973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34611920">
<a name="34611920"></a>Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and psoriasis: a systematic review, meta- and network meta-analysis. <i>Br J Clin Pharmacol</i>. Published online October 5, 2021. doi:10.1111/bcp.15060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/34611920/pubmed" id="34611920" target="_blank">34611920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31487643">
<a name="31487643"></a>Taguchi R, Naito T, Kubono N, Ogawa N, Itoh H, Kawakami J. Relationships between endogenous CYP3A markers and plasma amlodipine exposure and metabolism in early postpartum and non-peripartum women with hypertension.<i> Pregnancy Hypertens.</i> 2019;17:209-215. doi:10.1016/j.preghy.2019.07.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/31487643/pubmed" id="31487643" target="_blank">31487643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10454779">
<a name="10454779"></a>Tallian KB, Nahata MC, Turman MA, et al, “Efficacy of Amlodipine in Pediatric Patients With Hypertension,” <i>Pediatr Nephrol</i>, 1999, 13(4):304-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/10454779/pubmed" id="10454779" target="_blank">10454779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12210888">
<a name="12210888"></a>Teive HA, Germiniani FM, Werneck LC. Parkinsonian syndrome induced by amlodipine: case report. <i>Mov Disord</i>. 2002;17(4):833-835. doi:10.1002/mds.10185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/12210888/pubmed" id="12210888" target="_blank">12210888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24188181">
<a name="24188181"></a>Vasa R, Martha Ramirez M. Abstracts of the Academy of Breastfeeding Medicine 18th Annual International Meeting. Amlodipine exposure through breastfeeding in a 32 week preterm newborn. Philadelphia, Pennsylvania, USA. November 21-24, 2013. <i>Breastfeed Med</i>. 2013;(8 suppl):S2-22. doi:10.1089/bfm.2013.9982<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/24188181/pubmed" id="24188181" target="_blank">24188181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11069440">
<a name="11069440"></a>Vincent J, Harris SI, Foulds G, et al, “Lack of Effect of Grapefruit Juice on the Pharmacokinetics and Pharmacodynamics of Amlodipine,” <i>Br J Clin Pharmacol</i>, 2000, 50(5):455-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/11069440/pubmed" id="11069440" target="_blank">11069440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11439313">
<a name="11439313"></a>von Vigier RO, Franscini LM, Bianda ND, et al, "Antihypertensive Efficacy of Amlodipine in Children With Chronic Kidney Diseases," <i>J Hum Hypertens</i>, 2001, 15(6):387-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/11439313/pubmed" id="11439313" target="_blank">11439313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31107359">
<a name="31107359"></a>Vukadinović D, Scholz SS, Messerli FH, et al. Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. <i>J Hypertens</i>. 2019;37(10):2093–2103. doi:10.1097/HJH.0000000000002145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/31107359/pubmed" id="31107359" target="_blank">31107359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in <i>Hypertension</i>. 2018;71(6):e140-e144]. <i>Hypertension</i>. 2018;71(6):e140-e144. doi: 10.1161/HYP.0000000000000065.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wigley.1">
<a name="Wigley.1"></a>Wigley FM. Treatment of Raynaud phenomenon: Initial management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 31, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wigley.2">
<a name="Wigley.2"></a>Wigley FM, Herrick AL, Flavahan NA, eds. <i>Raynaud's Phenomenon: A Guide to Pathogenesis and Treatment</i>. New York, NY: Springer; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26370296">
<a name="26370296"></a>Yu P, Diao W, Tang Q, Jiang X. A successful pregnancy and parturition in a patient with anuria undergoing maintenance hemodialysis for 6 years: a case report of a 3-year-follow-up. <i>BMC Pregnancy Childbirth</i>. 2015;15:218. doi: 10.1186/s12884-015-0642-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/26370296/pubmed" id="26370296" target="_blank">26370296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15106034">
<a name="15106034"></a>Zinsser P, Meyer-Wyss B, Rich P. Hepatotoxicity induced by celecoxib and amlodipine. <i>Swiss Med Wkly</i>. 2004;134(13-14):201.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/15106034/pubmed" id="15106034" target="_blank">15106034</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12603 Version 703.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
